自我監測血糖設備市場、機會、成長動力、產業趨勢分析與預測，2024-2032

在第 1 型糖尿病盛行率不斷上升的推動下，自我監測血糖設備市場規模在 2024 年至 2032 年期間將以 11.6% 的複合年成長率成長。據世界衛生組織稱，全球約有 4.22 億人患有糖尿病，其中大多數居住在低收入和中等收入國家。每年，糖尿病直接導致全球 150 萬人死亡。 1 型糖尿病需要持續監測血糖水平，因此需要使用可靠的 SMBG 設備。對這種疾病及其早期診斷的更廣泛認知正在推動 SMBG 技術的進步，從而導致更準確、方便用戶使用和創新設備的開發。

現代 SMBG 設備可提供更高的血糖測量精度，減少錯誤並確保資料可靠，以實現有效的糖尿病管理。使用者友善的設計，包括簡單的介面、最少的血液樣本要求和快速的結果顯示，使這些設備更容易被更廣泛的使用者使用，包括老年人和技術能力有限的人。此外，自動資料記錄、與行動應用程式整合和語音指導指令等進步進一步簡化了監測過程，提高了患者的依從性和整體滿意度。

自我監測血糖設備產業根據產品、應用、最終用途和地區進行分類。

到 2032 年，1 型糖尿病市場將快速成長，因為它需要持續監測血糖水平。血糖儀、試紙和刺血針等自我監測血糖 (SMBG) 設備已成為第 1 型糖尿病患者有效管理病情的重要工具。準確性的提高、易用性以及與數位健康平台的整合是這些設備在第 1 型糖尿病患者中廣泛採用的關鍵因素。

到 2032 年，家庭護理領域將實現穩定成長。 SMBG 設備與智慧型手機和遠距醫療平台的整合進一步促進了遠端監控和諮詢，提高了患者的依從性和整體疾病管理。

在糖尿病高盛行率、有利的醫療政策和技術進步的共同推動下，歐洲自我血糖監測設備產業將在 2024 年至 2032 年期間大幅成長。歐洲醫療保健系統對預防保健和慢性病管理的重視支持了自我監測設備的廣泛使用。此外，旨在減輕糖尿病負擔的政府措施和報銷政策正在鼓勵整個歐洲採用 SMBG 設備。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 全球糖尿病盛行率上升
    • 已開發國家的技術進步
    • 政府為提高人們的意識而採取的舉措
  • 產業陷阱與挑戰
    • 發展中國家的先進設備和配件成本高昂
    • SMBG 設備缺乏報銷和嚴格的法規
• 成長潛力分析
• 監管環境
• 技術景觀
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2018 年 - 2032 年

• 主要趨勢
• 自我監測血糖儀
• 耗材
  • 測試條
  • 柳葉刀

第 6 章：市場估計與預測：按應用分類，2018 年 - 2032 年

• 主要趨勢
• 1 型糖尿病
• 2型糖尿病
• 妊娠糖尿病

第 7 章：市場估計與預測：按最終用途，2018 - 2032 年

• 主要趨勢
• 醫院
• 門診手術中心
• 診斷中心
• 居家護理
• 其他最終用戶

第 8 章：市場估計與預測：按地區分類，2018 年 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• Abbott Laboratories
• AgaMatrix
• All Medicus Co., Ltd.
• Arkray, Inc.
• Ascensia Diabetes Care Holdings AG
• B. Braun Melsungen AG
• Bionime Corporation
• DarioHealth Corp.
• Dexcom, Inc.
• Essenlife Bioscience, Inc.
• F. Hoffmann-La Roche Ltd.
• LifeScan Inc.
• Medtronic plc
• Nova Biomedical, Inc.
• Sinocare Inc.

The Self-monitoring Blood Glucose Devices Market size will grow at an 11.6% CAGR during 2024-2032, driven by the increasing prevalence of Type 1 diabetes. According to WHO, approximately 422 million people globally are living with diabetes, with the majority residing in low- and middle-income countries. Each year, diabetes directly accounts for 1.5 million deaths worldwide. Type 1 diabetes requires continuous monitoring of blood glucose levels, necessitating the use of reliable SMBG devices. The wider awareness about the condition and its early diagnosis is driving advancements in SMBG technology, leading to the development of more accurate, user-friendly, and innovative devices.

Modern SMBG devices offer higher precision in blood glucose measurements, reducing errors and ensuring reliable data for effective diabetes management. User-friendly designs, including simple interfaces, minimal blood sample requirements, and rapid result display, are making these devices more accessible to a broader range of users, including the elderly and those with limited technical skills. Additionally, advancements such as automated data logging, integration with mobile apps, and voice-guided instructions are further simplifying the monitoring process, enhancing patient compliance and overall satisfaction.

The self-monitoring blood glucose devices industry is classified based on product, application, end-use, and region.

The type 1 diabetes segment will grow rapidly through 2032, as it necessitates continuous monitoring of blood glucose levels. Self-monitoring blood glucose (SMBG) devices, such as glucometers, test strips, and lancets, have become essential tools for individuals with Type 1 diabetes to manage their condition effectively. Enhanced accuracy, ease of use, and integration with digital health platforms are among the key factors contributing to the widespread adoption of these devices among Type 1 diabetes patients.

The home care segment will witness steady growth through 2032. Home care offers a convenient and cost-effective alternative to hospital visits, allowing patients to monitor their blood glucose levels in the comfort of their homes. The integration of SMBG devices with smartphones and telehealth platforms further facilitates remote monitoring and consultation, enhancing patient compliance and overall disease management.

Europe self-Monitoring blood glucose devices industry will significantly over 2024-2032, driven by a combination of high diabetes prevalence, favorable healthcare policies, and technological advancements. The European healthcare system's emphasis on preventive care and chronic disease management supports the widespread use of self-monitoring devices. Additionally, government initiatives and reimbursement policies aimed at reducing the burden of diabetes are encouraging the adoption of SMBG devices across Europe.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of diabetes worldwide
    • 3.2.1.2 Technological advancements in developed countries
    • 3.2.1.3 Government initiatives for increasing awareness among people
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of advanced devices and accessories in developing countries
    • 3.2.2.2 Lack of reimbursement and stringent regulations for SMBG devices
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Self-monitoring blood glucose meters
• 5.3 Consumables
  • 5.3.1 Testing strips
  • 5.3.2 Lancets

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Type 1 diabetes
• 6.3 Type 2 diabetes
• 6.4 Gestational diabetes

Chapter 7 Market Estimates and Forecast, By End-use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgery centers
• 7.4 Diagnostic centers
• 7.5 Home care
• 7.6 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 AgaMatrix
• 9.3 All Medicus Co., Ltd.
• 9.4 Arkray, Inc.
• 9.5 Ascensia Diabetes Care Holdings AG
• 9.6 B. Braun Melsungen AG
• 9.7 Bionime Corporation
• 9.8 DarioHealth Corp.
• 9.9 Dexcom, Inc.
• 9.10 Essenlife Bioscience, Inc.
• 9.11 F. Hoffmann-La Roche Ltd.
• 9.12 LifeScan Inc.
• 9.13 Medtronic plc
• 9.14 Nova Biomedical, Inc.
• 9.15 Sinocare Inc.